PRESS RELEASE

Nanospectra Biosciences Technology Advances Partner Products to US Commercialization

Oct 30, 2018

HOUSTON, TX – October 30, 2018 – Nanospectra Biosciences, Inc., a medical device company pioneering a novel use of nanomedicine for selective thermal ablation, today announced that two of its commercial partners, Sebacia, Inc. and LiteCure, LLC, have advanced towards commercialization and indicated plans for commercial launch in the United States in 2019.

Sebacia, an exclusive licensee of Nanospectra intellectual property for the use of proprietary microparticles in the treatment of moderate to severe acne, recently announced Food and Drug Administration (FDA) clearance for its lead product, Sebacia Microparticles, triggering a strategic milestone payment to Nanospectra. As the supplier of a key component of Sebacia Microparticles used in Sebacia’s clinical efforts, Nanospectra is in discussions with Sebacia on supply of the component product for their intended commercialization efforts. Sebacia Microparticles is now commercially cleared in both the US and the EU – the two largest dermatology markets in the world.

LiteCure, through its veterinary division, Companion Animal Health, has an exclusive license and commercialization partnership with Nanospectra for the use of nanoshells in veterinary medicine for the ablative treatment of solid tumors and surface lesions in companion animals. In 2017, LiteCure initiated clinical trials in the treatment of a variety of companion animal cancers, primarily mast cell tumors in dogs using a laser and Nanospectra’s proprietary nanoshells. The combined therapy procedure demonstrated the ability to ablate solid tumors without undue damage to adjacent healthy tissue. In a presentation at the Annual Conference of the Veterinary Cancer Society, Dr. Lisa Parshley, of Olympia Veterinary Cancer Center, presented the latest clinical findings demonstrating a high degree of effectiveness in the ablation of canine and feline mast cell tumors, soft tissue sarcomas, squamous cell carcinomas and other tumor types. Companion Animal Health anticipates product launch of Companion Nano Therapy in the first half of 2019 for which Nanospectra will be the exclusive supplier of the core nanoparticles.

“We are excited to see the significant milestones that our commercial partners have achieved,” said David Jorden, CEO of Nanospectra. “Their success and visible path to commercialization is a validation of our enabling technology and our strategic plan to broaden therapeutic indications of our proprietary nanoshells.”

About Nanospectra Biosciences
Nanospectra Biosciences is a privately-held medical device company, pioneering the patient-centric use of nanomedicine for selective thermal ablation. AuroLase®, the company’s lead product, is the first ultra-focal therapy for prostate cancer. Nanospectra’s ultra-focal approach maximizes treatment efficacy while minimizing side effects associated with current treatments, including surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra’s technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.

For more information visit http://www.nanospectra.com.

Contact Information
Joleen Schultz
Joleen@joleenschultzassociates.com
Cell: 760-271-8150